Organic Active Ingredients TRIZ Cases

A crossflow membrane emulsification apparatus disperses lipid phases into aqueous streams to form uniform vesicle suspensions.

A rectal mucosal administration preparation combines Pulsatilla chinensis saponin B4 with a pharmaceutically acceptable substrate to enhance drug absorption.

Chimeric proteins bind non-cellular structures to deliver therapeutic signals, resolving the trade-off between targeting reliability and agent versatility.

Segmented capsules with permeable membranes reduce peak plasma levels and OCT2 inhibition to protect renal function.

A solid pharmaceutical composition with an inner cellulose-based polymer and outer enteric coating delivers tiopronin via delayed intestinal release.

Benzopyran compounds target cancer stem cells to reduce recurrence by inhibiting self-renewal pathways while maintaining safety margins.

Beta-cyclodextrin prevents ultra-fine ginseng powder aggregation through electrostatic repulsion, maximizing ginsenoside dissolution.

Formula I steroid derivatives modulate FXR activity, resolving limited therapeutic efficacy of existing ligands.

Washing wet enzalutamide with isopropyl acetate and n-heptane prevents B-type solvate formation during drying.

Macrocyclic indolin-2-one compounds inhibit Aurora and CDK kinases, addressing aberrant proliferation through multi-target action.

Non-homologous end joining enables high-frequency DNA sequence replacement without insertions or deletions in non-dividing cells.

DMSO enhances penetration of lidocaine and anti-inflammatory agents in a topical composition, addressing limited efficacy of existing treatments.

A process for preparing 2-amino-1,3-propane diol compounds uses diethylacetamido malonate to produce the target molecule.

Combining a liver-selective glucokinase activator with incretin-based agents restores insulin sensitivity and reduces body weight.

Compound A induces cell cycle arrest and apoptosis in prostate cancer cells, overcoming resistance to androgen deprivation therapy.

Catalytic oximes regenerate hBChE activity, enabling efficient organophosphate detoxification without stoichiometric protein consumption.

A DDR1 inhibitor slows articular chondrocyte terminal differentiation and apoptosis to preserve joint tissue integrity.

Tetrahydropyrrolopyridone compounds inhibit HIF prolyl hydroxylases to modulate hypoxia-inducible factor levels.

Pyridazinone compounds inhibit fast-twitch myosin to reduce contraction-induced damage in neuromuscular disease treatment.

Bisfluoroalkyl-1,4-benzodiazepinone compounds inhibit gamma secretase to suppress tumor growth in adenoid cystic carcinoma refractory to standard therapies.

Biomass-derived chelating agents encapsulate iron ions to enhance nutrient solubility and availability for plant uptake.

Monitoring blood miR-143 and miR-145 levels predicts chronic phase cardiac function after acute myocardial infarction.

Formula I furopyridine compounds inhibit HCV NS5B polymerase, reducing viral RNA levels while minimizing hepatic toxicity.

Tafasitamab targets CD19 antigens on B-cell malignancies to deliver cytotoxic effects via NK cell engagement.

Metastable bictegravir sodium Form II crystalline polymorph enhances solubility and dissolution rates for pharmaceutical applications.

Quinone-based cosmetic compositions reduce DNA damage by up to 80% while enhancing wound healing via CUL4A ubiquitin ligase inhibition.

NorA peptide inhibitors bind the efflux pump to block antibiotic expulsion, restoring intracellular drug concentration against resistant Staphylococcus aureus.

Sequential hormone and ferroptosis agent administration upregulates PSMA targets to enhance tumor regression.

A single daily subcutaneous iloprost injection formulation stabilizes drug levels using phospholipids and oils.

OLHHA addresses inadequate NASH therapies by reducing liver fat mass and inflammation through specific gene expression alterations.

Liquid oncology dosage form enables flexible pediatric dosing by allowing precise volume titration of active ingredients.

TRPC4/5 channel antagonists inhibit Gq-coupled Ca2+ influx to prevent epileptogenesis and seizures in traumatic brain injury.

Chemical modification of kynurenine generates TEACOPs that overcome structural incompatibility to deliver high-affinity AHR activation.

S-Hydroxychloroquine composition inhibits beta2-glycoprotein I conformational changes to treat antiphospholipid syndrome.

A microfluidic transdermal device integrates reservoirs and channels with microneedles to transport benefit agents across the skin barrier.

Transfection enhancing agents like MESNA improve nucleic acid uptake in respiratory tissues while reducing systemic exposure.

Replacing retinoids with magnolia bark extract and hyaluronic acid achieves skin tightening without severe irritation or oxidative decay.

Replacing complex biological fermentation, this chemical synthesis uses inexpensive chiral reagents to produce R- or S-equol efficiently.

Thylakoid extract lowers hsCRP levels by 25% to address chronic inflammation and oxidative stress in cardiovascular disease treatment.

Mutated suppressor tRNAs recognize premature stop codons to restore translation, producing functional proteins for genetic disorders like Dravet Syndrome.

An oral composition raises oxidation-reduction potential using zinc and cetylpyridinium chloride.

Oral chewable compositions with vitamins C, E, green tea extract, and gallic acid reduce UVB-induced oxidative stress without topical application drawbacks.

Benzothiophene-based activators improve PPARδ binding affinity and selectivity, addressing insufficient specificity of existing metabolic disease treatments.

A liposome production method uses mixed organic solvents to dissolve lipids and form stable vesicles.

Specific pyrimidine structures achieve selective FGFR4 inhibition, addressing the trade-off between broad efficacy and receptor specificity.

Mixing 5-aminolevulinic acid into cow feed bypasses rumen decomposition to raise casein concentration while maintaining fat content.

Segmented phenolic structures with fluorine substitutions enhance androgen receptor modulation to treat prostate cancer.

EIDD-1931 nucleoside analogue inhibits viral RNA synthesis, reducing enterovirus replication and alleviating severe infection symptoms.